Antibodies and vaccines for use in therapeutic and diagnostic methods for α-synuclein-related disorders
US8809506B2 · kind B2 · utility
Assignee
Inventors
Key dates
| Filing date | Apr 28, 2009 |
| Grant date | Aug 19, 2014 |
| Priority date | — |
| Expiry date | Dec 21, 2029 |
Classification
- Technology area (CPC Y)Emerging Cross-Sectional Technologies
- CPC primaryY10S530/839
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
A vaccine for delaying an onset of or for treatment of an α-synuclein-related disorder in an individual comprises a therapeutically effective amount of isolated stabilized soluble α-synuclein oligomer having a lower formation rate to a non-soluble aggregated form than a non-stabilized oligomer of the α-synuclein. An antibody for delaying an onset of or for treatment of an α-synuclein-related disorder in an individual binds soluble α-synuclein. Methods for delaying an onset of for treatment or for prevention of an α-synuclein-related disorder employ the vaccine or antibody. Methods of detecting α-synuclein oligomers employ the antibody.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.